Clinical Trials Logo

Clinical Trial Summary

This is an investigator-initiated Phase 2 study, which combines R-EDOCH with Ibrutinib to treat patients with Ritcher Transformation in consideration of DLBCL and CLL components both could being targeted at the same time. The investigator will observe the 2-year overall survival rate of this regimen for RT and explore the new regimen for RT in the novel drugs era, which aims to improve the efficacy and prolong survival.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04992377
Study type Interventional
Source Institute of Hematology & Blood Diseases Hospital
Contact Tingyu Wang
Phone +86 15692201678
Email wangtingyu@ihcams.ac.cn
Status Not yet recruiting
Phase Phase 2
Start date August 30, 2021
Completion date August 30, 2025

See also
  Status Clinical Trial Phase
Recruiting NCT05107674 - A Study of NX-1607 in Adults With Advanced Malignancies Phase 1
Recruiting NCT05828589 - A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies Phase 1
Active, not recruiting NCT04271956 - Efficacy and Safety of Zanubrutinib Plus Tislelizumab for Treatment of Patients With Richter Transformation Phase 2
Recruiting NCT04771572 - Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL. Phase 1